Search

ATLANTA, June 5, 2006 - A new multicenter study is the first to suggest that the prophylactic removal of the ovaries and fallopian tubes may provide a different benefit for women who carry a genetic mutation in the BRCA2 gene than for those who have a BRCA1 genetic mutation. The results of the study, which are being presented today at the annual American Society of Clinical Oncology meeting, also provide the strongest evidence to date that this surgery significantly reduces the overall risk of BRCA-associated breast and ovarian cancers.

… Monday, June 5, 2006 A new multicenter study is the first to suggest that the prophylactic removal of the ovaries and fallopian tubes may provide a different benefit for women who carry a genetic mutation in the BRCA2 gene than for those who have a BRCA1 genetic mutation. The results of the study, which

Learn how a clinical trial for a new type of immunotherapy called TCR therapy benefited a patient with synovial sarcoma.

… Wednesday, July 16, 2025 It was hard enough the first time Conor Handley was diagnosed with cancer, at age 17. He had a rare soft tissue cancer called synovial sarcoma. Then three years after finishing treatment, early in his senior year of college, came the devastating news: His synovial sarcoma was

Learn how molecular analysis of Jason’s sarcoma led to a personalized immunotherapy treatment that dramatically improved his prognosis. MSK is a leader in treating sarcoma.

… Monday, July 18, 2022 Thirty-four-year-old Jason Mascolo put off getting the nagging pain in his leg checked out for years because he didn’t have health insurance. It wasn’t until he got a job with benefits — as a utility worker with Consolidated Edison — that he went to see a doctor. The news was not

Results from studies in cell cultures and mouse models suggest that the experimental targeted therapy PU-H71 may be effective against one of the most aggressive forms of breast cancer.

… Thursday, October 1, 2009 Summary Results from studies in cell cultures and mouse models suggest that the experimental targeted therapy PU-H71 may be effective against one of the most aggressive forms of breast cancer. Results from studies in cell cultures and mouse models suggest that the experimental

Active surveillance of prostate cancer is being increasingly utilized for men with low-risk cancer. But some men with potentially life-threatening cancers are being inadvertently enrolled in such programs, driving the need for more accurate decision-making tools such as the 4Kscore test developed at Memorial Sloan Kettering.

… Thursday, October 12, 2017 Active surveillance of prostate cancer is being increasingly utilized for men with low-risk cancer. But some men with potentially life-threatening cancers are being inadvertently enrolled in active surveillance programs, driving the need for more-accurate decision-making tools

The experimental drug selumetinib may allow some patients with advanced thyroid cancer to overcome resistance to radioiodine (RAI), the most effective therapy for the disease, according to new research from Memorial Sloan Kettering Cancer Center.

… Wednesday, February 13, 2013 The experimental drug selumetinib may allow some patients with advanced thyroid cancer to overcome resistance to radioiodine (RAI), the most effective therapy for the disease, according to new research from Memorial Sloan Kettering Cancer Center. Published in the February

In order to preserve healthcare resources and provide exceptional care, our teams have been working together to develop new and innovative ways to treat our patients during the COVID-19 pandemic. MSK radiation oncologists rapidly re-evaluated our rectal cancer practice policies during this public health emergency.

… Friday, May 15, 2020 Cancer care is essential and should not be put on hold. Here at Memorial Sloan Kettering (MSK) we’ve put in place the strictest safety measures to ensure our patients continue to receive world-class cancer care in the safest environment possible. In order to preserve healthcare resources

Spinal cord compression due to spinal metastases is a medical emergency. Modern treatment approaches have fundamentally shifted the paradigm from providing short-term palliation and pain relief to delivering durable tumor control with fewer morbidities than older approaches. Therefore, cancer patients who have symptoms of spinal cord compression should be referred for surgical evaluation as soon as possible.

… Thursday, June 14, 2018 Spinal cord compression due to spinal metastases is a medical emergency. Modern treatment approaches — minimally invasive surgical techniques and spinal stereotactic radiosurgery (SSRS) — have fundamentally shifted the paradigm from providing short-term palliation and pain relief

The test, developed at MSK, looks for alterations in 468 genes that are seen in both common and rare cancers.

… Wednesday, November 15, 2017 Summary The FDA’s authorization of MSK-IMPACT sets a precedent for future authorization of tests developed by both academic and commercial labs. The US Food and Drug Administration has announced the authorization of MSK-IMPACT™ . The test was developed by Memorial Sloan Kettering

Originally explored as a cancer drug, the tree-derived chemical is now being mined for its antiviral properties.

… Monday, February 8, 2021 Summary Researchers at Memorial Sloan Kettering in collaboration with scientists in Germany have discovered that an investigational cancer drug has powerful effects against SARS-CoV-2, the virus that causes COVID-19. An investigational cancer drug with roots in the Malaysian